Core Insights - Coherus Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative cancer therapies in a highly competitive landscape alongside peers like Atara Biotherapeutics and FibroGen [1] Financial Performance - Coherus has a negative Return on Invested Capital (ROIC) of -153.12%, significantly lower than its Weighted Average Cost of Capital (WACC) of 11.27%, indicating inefficiencies in capital utilization [2][6] - In contrast, Atara Biotherapeutics demonstrates a strong financial position with a ROIC of 222.66% and a WACC of 5.98%, resulting in a ROIC to WACC ratio of 37.26, showcasing its efficiency in capital utilization [3][6] - Other peers like FibroGen have a ROIC of -50.80% and a WACC of 7.44%, indicating struggles but not as severe as Coherus [4] - The comparison of ROIC and WACC among these companies highlights the importance of these metrics in assessing financial health, with Coherus's negative ROIC to WACC ratio of -13.59 being a significant concern for investors [5][6]

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. on behalf of investors who acquired its securities during the specified class period from May 20, 2024, to January 9, 2026 [1] Summary by Relevant Sections - The lawsuit is initiated by the law firm Kirby McInerney LLP, indicating potential legal challenges for Atara Biotherapeutics [1] - Investors who suffered losses on their Atara investments are given a deadline of May 22, 2026, to request lead plaintiff appointment [1] - The court will not consider lead plaintiff applications submitted after the specified deadline [1]

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for allegedly misleading investors regarding its drug candidate tabelecleucel, which is intended for treating certain cancers and autoimmune diseases [1][2]. Group 1: Allegations and Issues - The lawsuit claims that Atara failed to disclose significant manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of tabelecleucel unlikely [2]. - It is alleged that the regulatory prospects of tabelecleucel were overstated, and the manufacturing issues increased the risk of regulatory scrutiny and jeopardized ongoing clinical trials [2]. - The complaint suggests that these undisclosed issues would likely have a significant negative impact on Atara's business and financial condition, rendering public statements materially false and misleading [2]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA on January 12, 2026, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their papers to the court by May 22, 2026, to serve as lead plaintiff, representing other class members [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Group 4: Company Background - Atara Biotherapeutics, Inc. focuses on developing therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the U.K., with its lead product candidate being tabelecleucel [1].

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for securities fraud, with a class period from May 20, 2024, to January 9, 2026, and investors are encouraged to participate as lead plaintiffs [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that Atara made false and misleading statements regarding manufacturing issues and regulatory prospects related to the tabelecleucel Biologics License Application (BLA), which could negatively impact the company's business and financial condition [5]. - Investors who purchased Atara securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation, and the deadline to move the Court for this role is May 22, 2026 [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for the number of securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and certain officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 26-cv-03083, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Atara securities between May 20, 2024 and Ja ...

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, alleging that the company misled investors regarding its business operations and regulatory prospects [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Atara Biotherapeutics made false and misleading statements about its manufacturing issues and the regulatory prospects of its tabelecleucel Biologics License Application (BLA), which were overstated [2]. - Specific allegations include that manufacturing deficiencies and issues with the ALLELE study made FDA approval unlikely, and these problems heightened regulatory scrutiny and jeopardized ongoing clinical trials [2]. - The lawsuit asserts that these misrepresentations had a significant negative impact on Atara's business and financial condition, leading to investor damages when the truth was revealed [2]. Group 2: Participation and Legal Representation - Shareholders wishing to act as lead plaintiffs in the class action must file motions with the court by May 22, 2026, and do not need to participate in the case to be eligible for recovery [2]. - Rosen Law Firm operates on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless they recover losses [3].

Group 1 - A shareholder class action lawsuit has been filed against Atara Biotherapeutics, alleging false and misleading statements regarding its business and operations [1] - The lawsuit claims that manufacturing issues and deficiencies in the ALLELE study make FDA approval of tabelecleucel unlikely, overstating its regulatory prospects [1] - The alleged manufacturing issues also increase the risk of regulatory scrutiny and jeopardize ongoing clinical trials, likely impacting Atara's business and financial condition negatively [1] Group 2 - Shareholders who purchased Atara shares between May 20, 2024, and January 9, 2026, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is May 22, 2026 [3] - Holzer & Holzer, LLC is a law firm specializing in shareholder class action litigation and has recovered hundreds of millions for shareholders affected by corporate misconduct [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed manufacturing issues affecting the company's product approval process [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Atara between May 20, 2024, and January 9, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff [4][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against Atara - The complaint alleges that Atara and its executives made false and misleading statements regarding manufacturing issues and the regulatory prospects of their product, tabelecleucel [6]. - Specific allegations include that manufacturing issues and deficiencies in the ALLELE study made FDA approval unlikely, overstating the product's regulatory prospects, and increasing the risk of regulatory scrutiny [6]. - The complaint asserts that these issues would likely have a significant negative impact on Atara's business and financial condition [6]. Group 3: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the EBVALLO™ Biologics License Application, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share on January 12, 2026 [7].

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for allegedly misleading investors regarding its drug candidate tabelecleucel, which has faced regulatory challenges from the FDA [1][2]. Group 1: Allegations and Issues - The lawsuit claims that Atara failed to disclose significant manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of tabelecleucel unlikely [2]. - It is alleged that the company overstated the regulatory prospects of tabelecleucel, leading to a heightened risk of regulatory scrutiny and jeopardizing ongoing clinical trials [2]. - The complaint indicates that these undisclosed issues were likely to have a significant negative impact on Atara's business and financial condition, rendering public statements materially false and misleading [2]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA on January 12, 2026, Atara's stock price dropped by $7.79 per share, or 56.99%, closing at $5.88 per share [3]. Group 3: Class Action Participation - Shareholders who wish to participate in the class action against Atara Biotherapeutics can contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [4].

Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...